pleased with our second quarter results and long-term trajectory. Luminex's strategic plan is focused on providing customers with the tools they need to positively impact human health through reduced complexity and increased speed of the testing process. We continue to invest heavily in our proprietary xMAP® technology, and we have always recognized that one platform may not suit all lab customer needs. In order to access these new opportunities, Luminex has sought to acquire external technologies, such as EraGen Biosciences in 2011 and our recent acquisition of GenturaDx," said Patrick J. Balthrop, president and chief executive officer of Luminex. "We are excited about GenturaDx technology and believe its simple to use, sample-to-answer platform combined with our proprietary MultiCode RTx chemistry will provide hospital-based molecular diagnostic labs with another powerful tool in their search for answers. When this system is commercialized (anticipated for 2014) Luminex will be able to offer our customers with a broad line of product solutions to fit their specific needs."
"Regarding new product updates, I am pleased to report that Luminex has submitted a de-novo 510(k) application to the FDA for our gastrointestinal pathogen panel (xTAG® GPP) assay. This product offering addresses a sizeable new market opportunity for Luminex and is another example of how Luminex is providing advanced solutions and real value to our customers. With new assays like GPP, NeoPlex4 and the exciting portfolio from Luminex Madison, we are positioned for strong growth in the future," Balthrop concluded.
REVENUE SUMMARY(in thousands, except percentages)Three Months EndedJune 30,Variance20122011($)(%)(unaudited)System sales
$ 8,386$ 9,135$
17,5109,2618,24989%All other revenue
3,8603,43342Page: 1 2 3 4 5 6 7 8 9 Related medicine technology :1
. Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 20122
. Luminex Corporation Announces Agreement to Acquire GenturaDx3
. Luminex Corporation Reports First Quarter 2012 Results4
. Unilife Corporation Announces Financial Results For Fiscal Year 2012 Fourth Quarter5
. Gentris Corporation Announces Collaboration to Study Blood Stability6
. Unilife Corporation to Announce Financial Results for Fiscal 2012 Fourth Quarter and Year End on Monday, July 30, 20127
. Volcano Corporation Schedules Second Quarter Conference Call, Webcast8
. Celladon Corporation Receives Patent from United States Patent and Trademark Office9
. Gentris Corporation Launches New Pharmacogenomics Services10
. BioElectronics Corporation Announces Initiative for UK and German Markets11
. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.